Zoetis (ZTS) Expected to Announce Earnings of $0.71 Per Share

Equities research analysts expect Zoetis (NYSE:ZTS) to post earnings per share of $0.71 for the current quarter, Zacks reports. Four analysts have made estimates for Zoetis’ earnings. The lowest EPS estimate is $0.69 and the highest is $0.73. Zoetis reported earnings per share of $0.53 in the same quarter last year, which suggests a positive year-over-year growth rate of 34%. The company is expected to announce its next quarterly earnings report on Tuesday, August 14th.

According to Zacks, analysts expect that Zoetis will report full-year earnings of $3.06 per share for the current year, with EPS estimates ranging from $2.96 to $3.10. For the next year, analysts forecast that the business will report earnings of $3.44 per share, with EPS estimates ranging from $3.38 to $3.56. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that follow Zoetis.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Wednesday, May 2nd. The company reported $0.75 EPS for the quarter, topping the consensus estimate of $0.69 by $0.06. Zoetis had a net margin of 17.97% and a return on equity of 68.51%. The business had revenue of $1.37 billion for the quarter, compared to analysts’ expectations of $1.35 billion. During the same quarter last year, the company posted $0.53 earnings per share. The company’s quarterly revenue was up 11.0% compared to the same quarter last year.

Several equities analysts have recently commented on the stock. Citigroup reissued a “buy” rating and issued a $98.00 target price (up previously from $85.00) on shares of Zoetis in a report on Thursday, April 19th. Hilliard Lyons cut shares of Zoetis to a “neutral” rating in a report on Thursday, April 19th. They noted that the move was a valuation call. Cantor Fitzgerald set a $90.00 target price on shares of Zoetis and gave the stock a “buy” rating in a report on Tuesday, April 24th. Morgan Stanley cut shares of Zoetis from an “overweight” rating to an “equal weight” rating and set a $70.00 target price on the stock. in a report on Monday, March 19th. They noted that the move was a valuation call. Finally, Craig Hallum reissued a “buy” rating and issued a $94.00 target price (up previously from $87.00) on shares of Zoetis in a report on Wednesday, April 25th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and thirteen have assigned a buy rating to the company’s stock. Zoetis currently has an average rating of “Buy” and a consensus target price of $82.67.

In other Zoetis news, EVP Roxanne Lagano sold 35,663 shares of the firm’s stock in a transaction that occurred on Wednesday, February 21st. The shares were sold at an average price of $81.02, for a total value of $2,889,416.26. Following the sale, the executive vice president now owns 49,919 shares in the company, valued at $4,044,437.38. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Heidi C. Chen sold 37,453 shares of the firm’s stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $81.02, for a total transaction of $3,034,442.06. The disclosure for this sale can be found here. Insiders sold 117,829 shares of company stock worth $9,626,877 in the last 90 days. 0.35% of the stock is owned by company insiders.

Several large investors have recently made changes to their positions in ZTS. Atria Investments LLC increased its stake in shares of Zoetis by 25.3% during the fourth quarter. Atria Investments LLC now owns 15,330 shares of the company’s stock valued at $1,104,000 after acquiring an additional 3,091 shares during the period. BLB&B Advisors LLC increased its stake in shares of Zoetis by 5.2% during the fourth quarter. BLB&B Advisors LLC now owns 50,460 shares of the company’s stock valued at $3,635,000 after acquiring an additional 2,478 shares during the period. Wendell David Associates Inc. increased its stake in shares of Zoetis by 8.4% during the fourth quarter. Wendell David Associates Inc. now owns 10,300 shares of the company’s stock valued at $742,000 after acquiring an additional 800 shares during the period. National Pension Service increased its stake in shares of Zoetis by 5.2% during the fourth quarter. National Pension Service now owns 458,095 shares of the company’s stock valued at $33,001,000 after acquiring an additional 22,829 shares during the period. Finally, Creative Planning increased its stake in shares of Zoetis by 19.9% during the fourth quarter. Creative Planning now owns 10,640 shares of the company’s stock valued at $767,000 after acquiring an additional 1,766 shares during the period. Institutional investors own 92.59% of the company’s stock.

Shares of Zoetis traded up $1.45, hitting $84.40, during trading hours on Tuesday, Marketbeat Ratings reports. 2,157,098 shares of the company were exchanged, compared to its average volume of 2,699,959. The company has a debt-to-equity ratio of 2.51, a quick ratio of 2.83 and a current ratio of 4.27. Zoetis has a one year low of $59.50 and a one year high of $86.38. The stock has a market capitalization of $40.84 billion, a price-to-earnings ratio of 35.17, a PEG ratio of 1.86 and a beta of 0.97.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 4th. Shareholders of record on Friday, July 20th will be paid a $0.126 dividend. The ex-dividend date of this dividend is Thursday, July 19th. This represents a $0.50 annualized dividend and a dividend yield of 0.60%. Zoetis’s payout ratio is currently 20.83%.

Zoetis Company Profile

Zoetis Inc discovers, develops, manufactures, and markets veterinary vaccines and medicines in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Get a free copy of the Zacks research report on Zoetis (ZTS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply